Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

The genomics of primary prostate cancer differ from those of metastatic castration-resistant
prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer …

Prostate cancer is the second most occurring cancer in men worldwide. To better
understand the mechanisms of tumorigenesis and possible treatment responses, we …

Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a
family history, new recommendations for germline and somatic testing, use of androgen …

The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a
pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of …

Aim Prostate cancer represents the most common cancer afflicting men. It may be
asymptomatic at the early stage. In this paper, we propose a methodology aimed to detect …

Several ongoing international prostate cancer (PC) clinical trials are exploring therapies that
target the DNA damage response (DDR) pathway. This systematic review summarizes the …

Importance Olaparib is a poly (adenosine diphosphate–ribose) polymerase inhibitor that
provides benefit in combination with hormonal therapies in patients with metastatic prostate …

Prostate-specific membrane antigen (PSMA)–targeting α-radiation therapy (TAT) is an
emerging treatment modality for metastatic castration-resistant prostate cancer. There is a …